AMERSFOORT, THE NETHERLANDS – Ingredient company FrieslandCampina Domo has entered into a joint venture with Glycosyn, Waltham, Mass., in the development of ingredients targeting infant nutrition. Glycosyn is a biotechnology company that develops products based on molecules found in human milk that may have health benefits.
“Human milk oligosaccharides are specialized carbohydrates that are naturally prevalent in mother’s milk,” said John R. Garrett, co-chief executive officer of Glycosyn. “Through our expertise and know-how we have developed technologies that will complement FrieslandCampina’s extensive history and knowledge of infant nutrition ingredients, products and markets.”
Glycosyn has developed a patented technology for the production of oligosaccharides from lactose. Through the agreement FrieslandCampina Domo will produce and introduce the new ingredients onto the global market.
 |
| Tine Snels, executive director of FrieslandCampina Ingredients |
“Glycosyn helps us to take a very exciting step towards developing the next generation of infant nutrition and to strengthen our position as a market leader in infant nutrition ingredients,” said Tine Snels, executive director of FrieslandCampina Ingredients. “We are doing this to meet the growing global demand for high-quality ingredients. Our cooperation is a perfect example of co-creation. The first quantities for trials will be available in the current year.”
